Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
Rhea-AI Summary
Aspire Biopharma (Nasdaq: ASBP) subsidiary Buzz Bomb Caffeine Company is launching a new BUZZ BOMB Convenience Store Pack, a six-count "Fruit Blast" offering with two each of Tropical Fruit, Mixed Berry, and Peach Mango.
Each single-serving stick contains 50mg fast-acting dry powder caffeine delivered under the tongue; rollout begins in select convenience stores starting in May.
Positive
- None.
Negative
- None.
News Market Reaction – ASBP
In the Mar 10 session, ASBP gained 1.67%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Drug partnership | Positive | +1.4% | Partnership to develop rapid-delivery sublingual alprazolam powder for anxiety relief. |
| Feb 25 | Marketing & sales | Positive | +3.6% | Buzz Bomb sponsorship drove record social media views and increased online revenue. |
| Feb 20 | Nasdaq compliance | Positive | -2.7% | Regained full compliance with Nasdaq listing requirements, including equity and bid price. |
| Feb 19 | PR agency mandate | Positive | -5.2% | Buzz Bomb appointed ChicExecs as PR agency to support brand expansion. |
| Feb 17 | Patent filing | Positive | +11.2% | Filed provisional patent for fast-acting sublingual meclizine powder targeting rapid relief. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often led to positive moves, though some operational and branding updates saw negative reactions.
Over the last month, ASBP announced a meclizine sublingual powder patent filing, Buzz Bomb branding and PR initiatives, a Nasdaq compliance update, and a new alprazolam partnership. These events produced mixed reactions, with notable gains of 11.19% on the meclizine filing and 3.62% on Buzz Bomb’s marathon-linked sales surge, but declines after the Nasdaq compliance and PR-agency news. Today’s convenience-store pack launch continues the BUZZ BOMB™ commercialization push highlighted in the February 19 and February 25 releases.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Convenient Size at the Convenience Store
ESTERO, FL / ACCESS Newswire / March 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), today announced that its subsidiary, Buzz Bomb Caffeine Company, is expanding its retail footprint with the launch of the BUZZ BOMB™ Convenience Store Pack.
Convenience stores are where many of today's quick decisions happen, and the checkout counter plays a big role in those moments. By introducing BUZZ BOMB™ into that space, we are giving the consumer greater choice and making BUZZ BOMB™ easier to enjoy and more accessible. This expansion is part of Buzz Bomb Caffeine Company's broader strategy to evolve with people's needs, energize convenience retail and drive growth across the caffeine category.
The Lineup
The lineup includes the newly designed six-count "Fruit Blast" package containing two each of the following flavors: Tropical Fruit, Mixed Berry, and Peach Mango, allowing for packaging options that fit changing habits.
BUZZ BOMB™ Convenience Store Pack
The Caffeine Evolution: No Liquid, No Limits
BUZZ BOMB™ is a fast-acting dry powder delivered in a single-serving stick pack designed to be sprinkled directly under the tongue. Unlike traditional energy drinks or pills, this serving method allows for a rapid caffeine boost without the need for water, mixing, or consuming large volumes of liquid.
Key Product Highlights:
Precision Dosing: Each stick pack delivers 50mg serving of caffeine.
Ultimate Portability: Slim, light, single-serving packs fit easily into pockets, gym bags, or car consoles.
Six pack "Fruit Blast" Offering: Featuring two each of the following flavors: Tropical Fruit, Mixed Berry, and Peach Mango.
Clean Energy: Ideal for athletes, professionals, and students seeking a quick, affordable alternative to coffee or soda.
"We are redefining how the world consumes caffeine," said Kraig Higginson, Interim CEO of Aspire Biopharma. "By moving into the convenience store sector, we are meeting our customers exactly where they need us-on the go, providing a precise, flavored caffeine hit that we believe works faster than a beverage."
The BUZZ BOMB™ Convenience Store Packs will begin appearing on shelves in select locations starting in May.
BUZZ BOMB™ Caffeine Products
Unlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.
BUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.
To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma delivers supplements to the body rapidly and precisely.
For more information, please visit www.aspirebiolabs.com
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire